Lantheus Holdings, Inc. · NASDAQ:LNTH

Lantheus — Q1 2024 Earnings Presentation

28 slides from Lantheus's earnings presentation, May 2, 2024

Slide 2: Presenters and agenda
Brian Markison Paul Blanchfield Bob Marshall Mark Kinarney CEO President CFO and Treasurer Vice President, Investor Relations Highlights & Business Update Commercial Update Pipeline Update Financial Update Closing Remarks Q&A 2 © 2024 Lantheus. All rights reserved.
Slide 3: Safe Harbor Statements
Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe har
Slide 5: Lantheus: The Leading Radiopharmaceutical-Focused Company
Lantheus: The Leading Radiopharmaceutical-Focused Company Strong Revenue, Total Revenue: $370.0M (+23.0%) Advancing Earnings and our purpose to Cash Flows1 Adjusted EPS: $1.69 (+15.2%) FIND. FIGHT. PYLARIFY remains clear market leader in FOLLOW. Sustained Growth Across Commercial Portfolio PSMA PET
Slide 7: PYLARIFY: Most Utilized PSMA PET Imaging Agent
Most Utilized PSMA PET Imaging Agent1 $258.9M +32.4% Growth 1Q 2024 Net Sales Year-Over-Year PYLARIFY delivers a best-in-class customer experience Driving growth through continued education to the prostate cancer community 1. Internal analyses and data on file. © 2024 Lantheus. All rights reserved.
Slide 8: Sustaining Brand Leadership
Most Utilized PSMA PET Imaging Agent1 SUSTAINING BRAND LEADERSHIP Widely available Expanded sales force Exploring clinical Differentiated clinical PSMA PET imaging Multifaceted Market to educate HCPs on utility of PYLARIFY and commercial agent through Access strategy the benefits of PSMA in addition
Slide 9: DEFINITY: Clear Market Leader in U.S. Ultrasound Enhancing Agents
Expanded indication to include pediatric patients1 Drivers of $76.6M Success 1Q 2024 Net Sales • Clinical and commercial value proposition +11.2% Growth • Decades of experience in clinical use Year-Over-Year • Operational excellence • Customer education efforts The Clear Market Leader in the U.S. Ul
Slide 11: Innovation that Makes an Impact
Innovation that Makes an Impact Maximizing the Value of Our Existing Portfolio and Expanding Our Pipeline PNT2002 • Met primary endpoint with PNT2003 • FDA accepted Abbreviated Late-stage, statistically significant Somatostatin New Drug Application (ANDA) – PSMA-targeted improvement in rPFS Receptor
Slide 12: The Leading Radiopharmaceutical-Focused Company
The Leading Radiopharmaceutical-Focused Company Market-leading commercial portfolio Successful commercial execution Fully integrated capabilities Actively evaluating M&A opportunities Sustaining an attractive financial profile Significant experience, capabilities and financial discipline to drive ne
Slide 14: Continued Strong Financial Performance in 1Q 2024
Continued Strong Financial Performance in 1Q 2024 Total Revenue $21.7 +23.0% (+3.5%) +$69.2M PYLARIFY $24.7 (+12.2%) DEFINITY $76.6 $354.0M $370.0 M (+11.2%) TechneLite $263.2M $300.8 M Strategic Partnerships & Other $258.9 Other Precision Diagnostics (+32.4%) Other Radiopharmaceutical Oncology 1Q 2
Slide 15: 1Q 2024 Financial Highlights
1Q 2024 Financial Highlights1 Adjusted Net Income Adjusted EPS +15.8% +15.2% +$16.2 118.3 $118.3 $1.79 $1.75 $1.69 +$0.22 $1.37 $1.47 $102.2 1Q 2023 1Q 2024 1Q 2023 1Q 2024 Cash and Cash Equivalents as of March 31, 2024: $718.3M 1. See slides 24 and 27 for a reconciliation of GAAP to non-GAAP financ
Slide 16: Growing Capital Resources Provide Financial Flexibility
Growing Capital Resources Provide Financial Flexibility1 USD Millions Cash Flow Summary Free Cash Flow2 Resources Three Months Ending March 31 (1Q 2024) +$19.6 2023 2024 INCREASE Cash provided by operations $108.5 $127.2 $718.3 $99.3 $119.0 CASH ON HAND3 Cash used in ($44.5) ($106.5) investing Cash
Slide 17: 2Q 2024 and Updated FY Financial Guidance
2Q 2024 and Updated FY Financial Guidance1 The Company guidance for the second quarter and full year 2024 is as follows: Revenue $380M - $390M 2Q 2024 Adjusted Fully Diluted EPS2 $1.81- $1.86 Revenue $1.50B - $1.52B FY 2024 Adjusted Fully Diluted EPS2 $7.00 - $7.20 Guidance Issued May 2, 2024 1. On
Slide 19: Lantheus, the Leading Radiopharmaceutical-Focused Company: Key Takeaways
Lantheus, the Leading Radiopharmaceutical-Focused Company Executing on Focused Strategy on advancement to drive near- and long-term and expansion growth of radiopharmaceutical pipeline 1Q 2024 >1.6M Key Takeaways PYLARIFY Continued Strong patient lives Clear market leader Performance impacted in as
Slide 24: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share data – unaudited) © 2024 Lantheus. All rights reserved. 24

Lantheus Holdings — Q1 2024 Earnings Presentation on 6ix

Lantheus — Q1 2024 Earnings Presentation

Slide 1: Lantheus First Quarter 2024 Results

Slide 2: Presenters and agenda

Slide 3: Safe Harbor Statements

Slide 4: Agenda

Slide 5: Lantheus: The Leading Radiopharmaceutical-Focused Company

Slide 6: Agenda

Slide 7: PYLARIFY: Most Utilized PSMA PET Imaging Agent

Slide 8: Sustaining Brand Leadership

Slide 9: DEFINITY: Clear Market Leader in U.S. Ultrasound Enhancing Agents

Slide 10: Agenda

Slide 11: Innovation that Makes an Impact

Slide 12: The Leading Radiopharmaceutical-Focused Company

Slide 13: Agenda

Slide 14: Continued Strong Financial Performance in 1Q 2024

Slide 15: 1Q 2024 Financial Highlights

Slide 16: Growing Capital Resources Provide Financial Flexibility

Slide 17: 2Q 2024 and Updated FY Financial Guidance

Slide 18: Agenda

Slide 19: Lantheus, the Leading Radiopharmaceutical-Focused Company: Key Takeaways

Slide 20: Agenda

Slide 21: Appendix

Slide 22: Condensed Consolidated Statement of Operations – 1Q 2024

Slide 23: As Adjusted Condensed Consolidated Statement of Operations – 1Q 2024

Slide 24: Reconciliation of GAAP to Non-GAAP Financial Measures

Slide 25: Consolidated Statement of Operations

Slide 26: Consolidated Segment Revenues Analysis

Slide 27: Reconciliation of Free Cash Flow

Slide 28: Condensed Consolidated Balance Sheet